Abstract
Objectives: To study the incidence of sudden unexpected death in epilepsy (SUDEP) after laser interstitial thermal therapy (LITT) for drug-resistant epilepsy (DRE).
Methods: Prospective observational study of consecutive patients treated with LITT between 2013-2021. The primary outcome was the occurrence of SUDEP during post-operative follow-up. Surgical outcome was classified according to the Engel scale.
Results: There were 5 deaths including 4 SUDEP among 135 patients with a median follow-up duration of 3.5 (range 0.1-9.0) years and a total of 501.3 person-years at risk. The estimated incidence of SUDEP was 8.0 (95% CI 2.2-20.4) per 1000 person-years. Three SUDEP deaths occurred in patients with poor seizure outcomes, whereas 1 patient was seizure-free. Compared to pooled historical data, SUDEP occurred at a higher rate than in cohorts treated with resective surgery and similar to non-surgical controls.
Discussion: SUDEP occurred early and late after mesial temporal LITT. The SUDEP rate was comparable to rates reported in epilepsy surgery candidates who did not receive intervention. These findings reinforce targeting seizure freedom to decrease SUDEP risk, including early consideration for further intervention.
Classification of evidence: This study provides Class IV evidence that LITT is not effective in reducing SUDEP incidence in patients with DRE.
- Received September 15, 2022.
- Accepted in final form March 28, 2023.
- © 2023 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
